Literature DB >> 21482602

Evaluation of immunization rates and safety among children with inborn errors of metabolism.

Nicola P Klein1, Laurie Aukes, Janelle Lee, Bruce Fireman, Stuart K Shapira, Barbara Slade, Roger Baxter, Marshall Summar.   

Abstract

BACKGROUND: Children with inherited metabolic disorders are a potential high-risk group for vaccine-preventable diseases, yet information regarding immunization rates and vaccine safety within this population is limited.
METHODS: Using Northern California Kaiser Permanente's electronic medical record, we identified children with inborn errors of metabolism from 1990 to 2007. We assessed immunization rates among infants with inborn errors of metabolism born at Northern California Kaiser Permanente matched to healthy infants (1 to 20), comparing both vaccines received by 2 years of age and age at vaccination. We assessed postvaccination adverse events among children up to 18 years old with inborn errors of metabolism, separately comparing emergency-department visits and hospitalizations during postvaccine days 0 to 30 (primary) and days 0 to 14 (secondary).
RESULTS: Comparing infants with inborn errors of metabolism (n = 77) versus matched control subjects (n = 1540), similar proportions were up to date for vaccines at 2 years of age, and there was no evidence of delay in receipt of recommended vaccines during the first year. Vaccination of children with inborn errors of metabolism (n = 271) was not associated with any significant increase in emergency-department visits or hospitalizations during the 30 days after vaccination. Secondary analyses suggested that there may be increased rates of hospitalizations 2 weeks after vaccination for the sickest 1- to 4-year-old children.
CONCLUSIONS: Children with inborn errors of metabolism at Northern California Kaiser Permanente received vaccines on the same immunization schedule as healthy infants. Immunization was not associated with increased risk for serious adverse events during the month after vaccination, providing overall reassurance that routine vaccination of children with inborn errors of metabolism does not result in adverse effects.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21482602     DOI: 10.1542/peds.2010-3706

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  12 in total

Review 1.  Acute management of propionic acidemia.

Authors:  Kimberly A Chapman; Andrea Gropman; Erin MacLeod; Kathy Stagni; Marshall L Summar; Keiko Ueda; Nicholas Ah Mew; Jill Franks; Eddie Island; Dietrich Matern; Loren Pena; Brittany Smith; V Reid Sutton; Tiina Urv; Charles Venditti; Anupam Chakrapani
Journal:  Mol Genet Metab       Date:  2011-09-24       Impact factor: 4.797

2.  Vaccines: The real issues in vaccine safety.

Authors:  Roberta Kwok
Journal:  Nature       Date:  2011-05-26       Impact factor: 49.962

Review 3.  The liver is a metabolic and immunologic organ: A reconsideration of metabolic decompensation due to infection in inborn errors of metabolism (IEM).

Authors:  Tatyana N Tarasenko; Peter J McGuire
Journal:  Mol Genet Metab       Date:  2017-06-24       Impact factor: 4.797

4.  Usefulness of biochemical parameters in decision-making on the start of emergency treatment in patients with propionic acidemia.

Authors:  Tamaris Zwickler; Alina Riderer; Gisela Haege; Georg F Hoffmann; Stefan Kölker; Peter Burgard
Journal:  J Inherit Metab Dis       Date:  2013-06-25       Impact factor: 4.982

Review 5.  Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society.

Authors:  Sumit Parikh; Amy Goldstein; Amel Karaa; Mary Kay Koenig; Irina Anselm; Catherine Brunel-Guitton; John Christodoulou; Bruce H Cohen; David Dimmock; Gregory M Enns; Marni J Falk; Annette Feigenbaum; Richard E Frye; Jaya Ganesh; David Griesemer; Richard Haas; Rita Horvath; Mark Korson; Michael C Kruer; Michelangelo Mancuso; Shana McCormack; Marie Josee Raboisson; Tyler Reimschisel; Ramona Salvarinova; Russell P Saneto; Fernando Scaglia; John Shoffner; Peter W Stacpoole; Carolyn M Sue; Mark Tarnopolsky; Clara Van Karnebeek; Lynne A Wolfe; Zarazuela Zolkipli Cunningham; Shamima Rahman; Patrick F Chinnery
Journal:  Genet Med       Date:  2017-07-27       Impact factor: 8.822

Review 6.  Vaccination of immune compromised children-an overview for physicians.

Authors:  Laure F Pittet; Klara M Posfay-Barbe
Journal:  Eur J Pediatr       Date:  2021-03-05       Impact factor: 3.183

7.  T-cell receptor excision circle levels and safety of paediatric immunization: A population-based self-controlled case series analysis.

Authors:  Kumanan Wilson; Daniel Rodriguez Duque; Malia S Q Murphy; Steven Hawken; Anne Pham-Huy; Jeffrey Kwong; Shelley L Deeks; Beth K Potter; Natasha S Crowcroft; Dennis E Bulman; Pranesh Chakraborty; Julian Little
Journal:  Hum Vaccin Immunother       Date:  2018-02-26       Impact factor: 3.452

8.  Immunological Memory and Affinity Maturation After Vaccination in Patients With Propionic Acidemia.

Authors:  Manuela Zlamy; Thomas Zöggeler; Magdalena Bachmann; Michael Schirmer; Christian Lechner; Miriam Michel; Alexander Schimkowitsch; Daniela Karall; Sabine Scholl-Bürgi
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

Review 9.  Kaiser Permanente Vaccine Study Center: Highlights of 2009-2012.

Authors:  Roger Baxter; Nicola P Klein
Journal:  Vaccines (Basel)       Date:  2013-04-25

Review 10.  Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia.

Authors:  Matthias R Baumgartner; Friederike Hörster; Carlo Dionisi-Vici; Goknur Haliloglu; Daniela Karall; Kimberly A Chapman; Martina Huemer; Michel Hochuli; Murielle Assoun; Diana Ballhausen; Alberto Burlina; Brian Fowler; Sarah C Grünert; Stephanie Grünewald; Tomas Honzik; Begoña Merinero; Celia Pérez-Cerdá; Sabine Scholl-Bürgi; Flemming Skovby; Frits Wijburg; Anita MacDonald; Diego Martinelli; Jörn Oliver Sass; Vassili Valayannopoulos; Anupam Chakrapani
Journal:  Orphanet J Rare Dis       Date:  2014-09-02       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.